Nadia H, Michael G. Breast cancer. Lancet. 2017. https://doi.org/10.1016/s0140-6736(16)31891-8.

Article  Google Scholar 

Freddie B, Mathieu L, Hyuna S, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CAA Cancer J Clin. 2022. https://doi.org/10.3322/caac.21834.

Article  Google Scholar 

Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49. https://doi.org/10.1038/s41392-024-02108-4.

Article  PubMed  PubMed Central  Google Scholar 

Haojia L, Arpit A, Paula T, et al. A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial. Lancet Digit Health. 2024. https://doi.org/10.1016/s2589-7500(24)00116-x.

Article  Google Scholar 

Lawrence JS. Management of ductal carcinoma in situ (DCIS) of the breast: present approaches and future directions. Curr Oncol Rep. 2019. https://doi.org/10.1007/s11912-019-0777-3.

Article  Google Scholar 

Van Mieke B, Jelle W, Ester HL, et al. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance. Breast Cancer Res. 2024. https://doi.org/10.1186/s13058-024-01875-w.

Article  Google Scholar 

Noyan S, Gür Dedeoğlu B. Upregulation of miR-99b-5p modulates ESR1 expression as an adaptive mechanism to circumvent drug response via facilitating ER/HER2 crosstalk. Balkan Med J. 2025;42:150–6. https://doi.org/10.4274/balkanmedj.galenos.2025.2024-12-47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomas AB, Mark RS, Jennifer JG, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II Invasive breast cancer: American Society of clinical oncology endorsement of the society of surgical oncology/American Society for radiation oncology Consensus guideline. J Clin Oncol. 2014. https://doi.org/10.1200/jco.2014.55.1572.

Article  PubMed  PubMed Central  Google Scholar 

Bernard F, James JD, John B, Norman W. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project b-14 randomized trial. JNCI J Natl Cancer Inst. 2001. https://doi.org/10.1093/jnci/93.9.684.

Article  Google Scholar 

Andrea LM, Suzanne BC, Rong T, et al. Implications of new lumpectomy margin guidelines for breast-conserving surgery: changes in reexcision rates and predicted rates of residual tumor. Ann Surg Oncol. 2015. https://doi.org/10.1245/s10434-015-4916-2.

Article  PubMed  Google Scholar 

Curigliano G, Burstein HJ, Gnant M, et al. Understanding breast cancer complexity to improve patient outcomes: the st Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34:970–86. https://doi.org/10.1016/j.annonc.2023.08.017.

Article  CAS  PubMed  Google Scholar 

Toi M, Kinoshita T, Benson JR, et al. Non-surgical ablation for breast cancer: an emerging therapeutic option. Lancet Oncol. 2024;25:e114–25. https://doi.org/10.1016/s1470-2045(23)00615-0.

Article  PubMed  Google Scholar 

Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023;73:480–515. https://doi.org/10.3322/caac.21777.

Article  PubMed  Google Scholar 

Agostinetto E, Gligorov J, Piccart M. Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol. 2022;19:763–74. https://doi.org/10.1038/s41571-022-00687-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, et al. 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. https://doi.org/10.1016/j.breast.2024.103756.

Article  PubMed  PubMed Central  Google Scholar 

McDonnell DP, Wardell SE, Chang CY, Norris JD. Next-generation endocrine therapies for breast cancer. J Clin Oncol. 2021;39:1383–8. https://doi.org/10.1200/jco.20.03565.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin X, Zhou YF, Ma D, et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023;55:1696–708. https://doi.org/10.1038/s41588-023-01507-7.

Article  CAS  PubMed  Google Scholar 

Zheng Y, Li S, Tang H, Meng X, Zheng Q. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front Immunol. 2023;14:1153990. https://doi.org/10.3389/fimmu.2023.1153990.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tufail M, Cui J, Wu C. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. Am J Cancer Res. 2022;12:2920–49.

CAS  PubMed  PubMed Central  Google Scholar 

Abdi E, Latifi-Navid S, Latifi-Navid H. LncRNA polymorphisms and breast cancer risk. Pathol Res Pract. 2021;229:153729. https://doi.org/10.1016/j.prp.2021.153729.

Article  CAS  PubMed  Google Scholar 

Ahmadpour ST, Orre C, Bertevello PS, et al. Breast cancer chemoresistance: insights into the regulatory role of lncRNA. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms242115897.

Article  PubMed  PubMed Central  Google Scholar 

Yang Q, Fu Y, Wang J, Yang H, Zhang X. Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer. J Zhejiang Univ Sci B. 2023;24:1123–40. https://doi.org/10.1631/jzus.B2300067.

Article  CAS  PubMed  Google Scholar 

Dvinge H, Git A, Gräf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497:378–82. https://doi.org/10.1038/nature12108.

Article  CAS  PubMed  Google Scholar 

Jin M, Fang J, Peng J, et al. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23:266. https://doi.org/10.1186/s12943-024-02176-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Syamsu SA, Faruk M, Smaradania N, et al. PD-1/PD-L1 pathway: current research in breast cancer. Breast Dis. 2024;43:79–92. https://doi.org/10.3233/bd-249006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei C, Kong X, Li Y, et al. PD-1/PD-L1 inhibitor - related adverse events and their management in breast cancer. J Cancer. 2024;15:2770–87. https://doi.org/10.7150/jca.85433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirzaei S, Ranjbar B, Tackallou SH, Aref AR. Hypoxia inducible factor-1α (HIF-1α) in breast cancer: the crosstalk with oncogenic and onco-suppressor factors in regulation of cancer hallmarks. Pathol Res Pract. 2023;248:154676. https://doi.org/10.1016/j.prp.2023.154676.

Article  CAS  PubMed  Google Scholar 

Shamis SAK, McMillan DC, Edwards J. The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103231. https://doi.org/10.1016/j.critrevonc.2021.103231.

Article  PubMed  Google Scholar 

Kozal K, Krześlak A. The role of hypoxia-inducible factor isoforms in breast cancer and perspectives on their inhibition in therapy. Cancers. 2022. https://doi.org/10.3390/cancers14184518.

Article  PubMed  PubMed Central  Google Scholar 

Jung O, Baek MJ, Wooldrik C, et al. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer. EMBO J. 2024;43:1740–69.